Current status of hepatocellular carcinoma treatment in Japan: Transarterial chemoembolization

Clinical Drug Investigation

Volumn 32, Issue SUPPL. 2, 2012, Pages 3-13

  Matsui, Osamu ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ERLOTINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IODINATED POPPYSEED OIL; MICROSPHERE; MITOMYCIN C; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POLYVINYL ALCOHOL; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; YTTRIUM 90;

ANGIOGENESIS; CANCER CONTROL; CANCER GRADING; CANCER SIZE; CANCER SURVIVAL; CELL PROLIFERATION; CHEMOEMBOLIZATION; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER SINUSOID; LOCAL RECURRENCE FREE SURVIVAL; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT RESPONSE; TUMOR VASCULARIZATION; UPREGULATION;

EID: 84864667059     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/1163021-s0-000000000-00000     Document Type: Review

References (43)

1. American Cancer Society. What is liver cancer? [online] Available from URL: http://www.cancer.org/Cancer/LiverCancer/DetailedGuide/liver-cancer-what- is-liver-cancer [Accessed 2011 Feb 3]
2. Gish RG, Marrero JA, Benson AB. A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterol Hepatol (NY) 2010; 6 (3 Suppl. 6): 1-16
3. Bruix J, Sherman M. AASLD Practice Guideline: Management of Hepatocellular Carcinoma: An Update [online]. Available at URL: http://www.aasld.org/practiceguidelines/Documents/ Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf [Accessed 2010 Nov 14]
4. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19 (3): 329-38
5. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37 (3): 212-20 [Epub 2010 Aug 17]
6. The Japan Society of Hepatology. The Japanese HCC Clinical Practice Guideline. Treatment algorithm for hepatocellular carcinoma. Hepatology Research 2010; 40 (Suppl. 1): 8-9
7. Ikai I, Kudo M, Arii S, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatology Research 2010; 40 (11): 1043-59
8. The Japan Society of Hepatology. The Japanese HCC Clinical Practice Guideline. Chapter 5: Transcatheter arterial chemoembolization. Hepatology Research 2010; 40 (Suppl. 1): 96-112
9. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30 (1): 6-25 (Pubitemid 44900485)
10. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 (Suppl. 1): S20-37
11. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35 (5): 1164-71 (Pubitemid 34454013)
12. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (1): 41-52
13. Matsui O, Miyayama S, Sanada J, et al. Interventional oncology: new options for interstitial treatments and intravascular approaches: superselective TACE using iodized oil for HCC: rationale, technique and outcome. J Hepatobiliary Pancreat Sci 2010; 17 (4): 407-9
14. Matsui O, Kobayashi S, Sanada J, et al. Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 2011; 36 (3): 264-72
15. Kobayashi S, Nakanuma Y, Matsui O. Intrahepatic peribiliary vascular plexus in various hepatobiliary diseases: a histological survey. Hum Pathol 1994; 25 (9): 940-6 (Pubitemid 24292413)
16. Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 2007; 18 (3): 365-76 (Pubitemid 46616707)
17. Matsui O, Kadoya M, Yoshikawa J, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993; 188 (1): 79-83 (Pubitemid 23183103)
18. Takayasu K, Muramatsu Y, Maeda T, et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol 2001; 176 (3): 681-8 (Pubitemid 32181966)
19. Matsuo N, Uchida H, Nishimine K, et al. Segmental transcatheter hepatic artery chemoembolization with iodized oil for hepatocellular carcinoma: antitumor effect and influence on normal tissue. J Vasc Interv Radiol 1993; 4 (4): 543-9
20. Murakami T, Ishimaru H, Sakamoto I, et al. Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Intervent Radiol 2007; 30 (4): 696-704 (Pubitemid 350092235)
21. Dharancy S, Boitard J, Decaens T, et al. Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: a casecontrol study. Liver Transpl 2007; 13 (5): 665-71 (Pubitemid 46796537)
22. Giannini EG, Bodini G, Corbo M, et al. Impact of evidencebased medicine on the treatment of patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 31 (4): 493-501
23. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131 (2): 461-9 (Pubitemid 44142456)
24. Olivo M, Valenza F, Buccellato A, et al. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors. Dig Liver Dis 2010; 42 (7): 515-9
25. Japanese Society of Hepatology. Japanese Clinical Practice Manual of Hepatocellular Carcinoma. 2nd ed. Tokyo: Igaku Shoin, 2010
26. Riaz A, Kulik L, Lewandowski RJ, et al. Radiologicpathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009; 49 (4): 1185-93
27. Kooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21 (2): 224-30
28. Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008; 8 (11): 1743-9
29. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7 (10): 3129-40
30. Bayer. Nexavar approved in Japan for the treatment of advanced liver cancer [press release online]. Available from URL: http://www.onyx-pharm.com/ view.cfm/589/Nex avar-Approved-in-Japan-for-the-Treatment-of-Advanced-Liver- Cancer. 2009: [Accessed 2011 Feb 3]
31. Arii S, Sata M, Sakamoto M, et al. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40 (7): 667-85
32. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285 (21): 1182-6
33. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004; 41 (5): 864-80 (Pubitemid 39434320)
34. Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3 (5): 515-20 (Pubitemid 27198648)
35. Nakamura K, Zen Y, Sato Y, et al. Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor-1alpha are involved in malignant transformation in dysplastic nodules of the liver. Hum Pathol 2007; 38 (10): 1532-46 (Pubitemid 47418965)
36. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307 (5706): 58-62 (Pubitemid 40093472)
37. Gupta S, Kobayashi S, Phongkitkarun S, et al. Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol 2006; 41 (6): 516-21 (Pubitemid 44284186)
38. Xiao EH, Guo D, Bian DJ. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells. World J Gastroenterol 2009; 15 (36): 4582-6
39. Wang B, Xu H, Gao ZQ, et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008; 49 (5): 523-9
40. Kim YB, Park YN, Park C. Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology 2001; 38 (2): 160-6 (Pubitemid 32193630)
41. Li X, Feng GS, Zheng CS, et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10 (19): 2878-82 (Pubitemid 39303010)
42. Shim JH, Park JW, Kim JH, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008; 99 (10): 2037-44
43. Okita K, Imanaka K, Chida N, et al. Phase III study of sorafenib in patients in Japan and Korea with advanced hepatocellular carcinoma (HCC) treated after transarterial chemoembolization (TACE). Abstract LBA128 presented at 2010 Gastrointestinal Cancers Symposium, Orlando, Florida, January 22-24. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&confID=72&abstractID=2287. 2010: [Accessed 2011 Feb 3]